May 2, 2024, 14:30
Glecirasib demonstrates efficacy in KRASG12C-mutated NSCLC – ASCO
American Society of Clinical Oncology (ASCO) shared on X:
“Breaking news from the ASCO Plenary Series:
Glecirasib demonstrates encouraging efficacy and safety in KRASG12C-mutated Non- Small Cell Lung Cancer (NSCLC) in phase 2 trial from China.
ASCO Daily News has more.”
Source: ASCO/X